Rapid Micro Biosystems to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
Rhea-AI Summary
Rapid Micro Biosystems, Inc. (Nasdaq: RPID), a life sciences technology company specializing in automation solutions for healthcare product manufacturing, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. The event is scheduled for September 6, 2024, in New York City.
Key details:
- President and CEO Rob Spignesi and CFO Sean Wirtjes will participate
- 35-minute Q&A session with the host analyst
- Session starts at 7:00 a.m. Eastern Time
- Live webcast available on the company's investor relations website
- Archived webcast will be accessible for replay after the event
This conference provides an opportunity for Rapid Micro Biosystems to showcase its innovative solutions and engage with industry professionals and investors.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, RPID gained 0.90%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
LEXINGTON, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that the Company will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference on Friday, September 6, 2024, in New York City.
Rob Spignesi, President and CEO, and Sean Wirtjes, CFO, are scheduled to participate in a 35-minute question-and-answer session with the host analyst at 7:00 a.m. Eastern Time. A live webcast of the session will be available on the Rapid Micro Biosystems investor relations website at https://investors.rapidmicrobio.com/ and can be accessed here. The webcast will be archived and available for replay after the event.
About Rapid Micro Biosystems
Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company’s flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control (“MQC”) testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct system brings the quality control lab to the manufacturing floor, unlocking the power of MQC automation to deliver the faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that customers rely on to ensure safe and consistent supply of important healthcare products. The Company is headquartered Lexington, Massachusetts and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Switzerland, Germany, and the Netherlands. For more information, please visit www.rapidmicrobio.com or follow the Company on X (formerly known as Twitter) at @rapidmicrobio or on LinkedIn.
FAQ
When is Rapid Micro Biosystems (RPID) participating in the Morgan Stanley Healthcare Conference?
Who will represent Rapid Micro Biosystems (RPID) at the Morgan Stanley Healthcare Conference?
What time is Rapid Micro Biosystems' (RPID) Q&A session at the Morgan Stanley conference?
How can investors access the webcast of Rapid Micro Biosystems' (RPID) conference session?
Will the webcast of Rapid Micro Biosystems' (RPID) Morgan Stanley conference session be available for replay?
